Restoration of MBL-deficiency: Redefining the safety, efficacy and viability of MBL-substitution therapy

Molecular Immunology

Volumn 61, Issue 2, 2014, Pages 174-184

  Keizer, M P ^a,b   Wouters, D ^a   Schlapbach, L J ^c   Kuijpers, T W ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Lectin pathway; MBL replacement therapy; MBL deficiency; MBL genotype

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FRESH FROZEN PLASMA; MANNOSE BINDING LECTIN; MBL ASSOCIATED SERINE PROTEASE; PLASMA DERIVED MANNOSE BINDING LECTIN; RECOMBINANT MANNOSE BINDING LECTIN; RECOMBINANT PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BACTERIAL INFECTION; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CHILDHOOD CANCER; CYSTIC FIBROSIS; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; GENOTYPE; HUMAN; MANNOSE BINDING LECTIN DEFICIENCY; NEWBORN SEPSIS; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; SUBSTITUTION THERAPY; VIRUS INFECTION;

LECTIN PATHWAY; MBL REPLACEMENT THERAPY; MBL-DEFICIENCY; MBL-GENOTYPE;

GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MANNOSE-BINDING LECTIN; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; METABOLISM, INBORN ERRORS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84907598527     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2014.06.005     Document Type: Review

References (135)

1. Adamek M., Heyder J., Heinold A., Fiedler G., Opelz G., Tran T.H. Characterization of mannose-binding lectin (MBL) variants by allele-specific sequencing of MBL2 and determination of serum MBL protein levels. Tissue Antigens 2013, 82:410-415.
2. Alexander S., Nieder M., Zerr D.M., Fisher B.T., Dvorak C.C., Sung L. Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn?. Pediatr. Blood Cancer 2012, 59:16-20.
3. Auriti C., Prencipe G., Inglese R., Azzari C., Ronchetti M.P., Tozzi A., Seganti G., Orzalesi M., De Benedetti F. Role of mannose-binding lectin in nosocomial sepsis in critically ill neonates. Hum. Immunol. 2010, 71:1084-1088.
4. Bang P., Laursen I., Thornberg K., Schierbeck J., Nielsen B., Valdimarsson H., Koch C., Christiansen M. The pharmacokinetic profile of plasma-derived mannan-binding lectin in healthy adult volunteers and patients with Staphylococcus aureus septicaemia. Scand. J. Infect. Dis. 2008, 40:44-48.
5. Basu S.K., Fernandez I.D., Fisher S.G., Asselin B.L., Lyman G.H. Length of stay and mortality associated with febrile neutropenia among children with cancer. J. Clin. Oncol. 2005, 23:7958-7966.
6. Berger S.P., Roos A., Mallat M.J., Fujita T., de Fijter J.W., Daha M.R. Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am. J. Transplant. 2005, 5:1361-1366.
7. Bouwman L.H., Roos A., Terpstra O.T., de Knijff P., van Hoek B., Verspaget H.W., Berger S.P., Daha M.R., Frolich M., van der Slik A.R., Doxiadis I.I., Roep B.O., Schaapherder A.F. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005, 129:408-414.
8. Bradley D.T., Bourke T.W., Fairley D.J., Borrow R., Shields M.D., Young I.S., Zipfel P.F., Hughes A.E. Genetic susceptibility to invasive meningococcal disease: MBL2 structural polymorphisms revisited in a large case-control study and a systematic review. Int. J. Immunogenet. 2012, 39:328-337.
9. Brouwer N., Frakking F.N., van de Wetering M.D., van Houdt M., Hart M., Budde I.K., Strengers P.F., Laursen I., Houen G., Roos D., Jensenius J.C., Caron H.N., Dolman K.M., Kuijpers T.W. Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels. J. Immunol. 2009, 183:3496-3504.
10. Casanova J.L., Abel L. Human genetics of infectious diseases: a unified theory. EMBO J. 2007, 26:915-922.
11. Cedzynski M., Szemraj J., Swierzko A.S., Bak-Romaniszyn L., Banasik M., Zeman K., Kilpatrick D.C. Mannan-binding lectin insufficiency in children with recurrent infections of the respiratory system. Clin. Exp. Immunol. 2004, 136:304-311.
12. Chalmers J.D., Fleming G.B., Hill A.T., Kilpatrick D.C. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 2011, 21:271-282.
13. Dahl M.R., Thiel S., Matsushita M., Fujita T., Willis A.C., Christensen T., Vorup-Jensen T., Jensenius J.C. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15:127-135.
14. de Rooij B.J., van der Beek M.T., van Hoek B., Vossen A.C., Rogier Ten Hove W., Roos A., Schaapherder A.F., Porte R.J., van der Reijden J.J., Coenraad M.J., Hommes D.W., Verspaget H.W. Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation. J. Hepatol. 2011, 55:800-807.
15. Dean M.M., Heatley S., Minchinton R.M. Heteroligomeric forms of codon 54 mannose binding lectin (MBL) in circulation demonstrate reduced in vitro function. Mol. Immunol. 2006, 43:950-961.
16. Degn S.E., Hansen A.G., Steffensen R., Jacobsen C., Jensenius J.C., Thiel S. MAp44, a human protein associated with pattern recognition molecules of the complement system and regulating the lectin pathway of complement activation. J. Immunol. 2009, 183:7371-7378.
17. Degn S.E., Jensen L., Hansen A.G., Duman D., Tekin M., Jensenius J.C., Thiel S. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function. J. Immunol. 2012, 189:3957-3969.
18. Degn S.E., Jensen L., Olszowski T., Jensenius J.C., Thiel S. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. J. Immunol. 2013, 191:1334-1345.
19. Dellinger R.P., Levy M.M., Carlet J.M., Bion J., Parker M.M., Jaeschke R., Reinhart K., Angus D.C., Brun-Buisson C., Beale R., Calandra T., Dhainaut J.F., Gerlach H., Harvey M., Marini J.J., Marshall J., Ranieri M., Ramsay G., Sevransky J., Thompson B.T., Townsend S., Vender J.S., Zimmerman J.L., Vincent J.L., International Surviving Sepsis Campaign Guidelines C., American Association of Critical-Care N., American College of Chest P., American College of Emergency P., Canadian Critical Care S., European Society of Clinical M., Infectious D., European Society of Intensive Care M., European Respiratory S., International Sepsis F., Japanese Association for Acute M., Japanese Society of Intensive Care M., Society of Critical Care M., Society of Hospital M., Surgical Infection S., World Federation of Societies of I., Critical Care M. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. Crit. Care Med. 2008, 36:296-327.
20. Dolman K.M., Brouwer N., Frakking F.N., Flatø B., Tak P.P., Kuijpers T.W., Førre O., Smerdel-Ramoya A. Mannose-binding lectin deficiency is associated with early onset of polyarticular juvenile rheumatoid arthritis: a cohort study. Arthritis Res. Ther. 2008, 10:R32.
21. Dommett R., Chisholm J., Turner M., Bajaj-Elliott M., Klein N.J. Mannose-binding lectin genotype influences frequency and duration of infectious complications in children with malignancy. J. Pediatr. Hematol. Oncol. 2013, 35:69-75.
22. Dommett R.M., Klein N., Turner M.W. Mannose-binding lectin in innate immunity: past, present and future. Tissue Antigens 2006, 68:193-209.
23. Dornelles L.N., Pereira-Ferrari L., Messias-Reason I. Mannan-binding lectin plasma levels in leprosy: deficiency confers protection against the lepromatous but not the tuberculoid forms. Clin. Exp. Immunol. 2006, 145:463-468.
24. Dzwonek A.B., Neth O.W., Thiebaut R., Gulczynska E., Chilton M., Hellwig T., Bajaj-Elliott M., Hawdon J., Klein N.J. The role of mannose-binding lectin in susceptibility to infection in preterm neonates. Pediatr. Res. 2008, 63:680-685.
25. Eisen D.P., Dean M.M., Boermeester M.A., Fidler K.J., Gordon A.C., Kronborg G., Kun J.F., Lau Y.L., Payeras A., Valdimarsson H., Brett S.J., Ip W.K., Mila J., Peters M.J., Saevarsdottir S., van Till J.W., Hinds C.J., McBryde E.S. Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin. Infect. Dis. 2008, 47:510-516.
26. Faber J., Schuessler T., Finn A., Murdoch C., Zenz W., Habermehl P., Meyer C.U., Zabel B.U., Schmitt H., Zepp F., Knuf M. Age-dependent association of human mannose-binding lectin mutations with susceptibility to invasive meningococcal disease in childhood. Pediatr. Infect. Dis. J. 2007, 26:243-246.
27. Fanaroff A.A., Stoll B.J., Wright L.L., Carlo W.A., Ehrenkranz R.A., Stark A.R., Bauer C.R., Donovan E.F., Korones S.B., Laptook A.R., Lemons J.A., Oh W., Papile L.A., Shankaran S., Stevenson D.K., Tyson J.E., Poole W.K., Network N.N.R. Trends in neonatal morbidity and mortality for very low birthweight infants. Am. J. Obstet. Gynecol. 2007, 196. pp. 147 e1-147 e8.
28. Forneris F., Wu J., Gros P. The modular serine proteases of the complement cascade. Curr. Opin. Struct. Biol. 2012, 22:333-341.
29. Frakking F.N., Brouwer N., van de Wetering M.D., Budde I.K., Strengers P.F., Huitema A.D., Laursen I., Houen G., Caron H.N., Dolman K.M., Kuijpers T.W. Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia. Eur. J. Cancer 2009, 45:505-512.
30. Frakking F.N., Israels J., Kremer L.C., Kuijpers T.W., Caron H.N., van de Wetering M.D. Mannose-binding lectin (MBL) and the risk for febrile neutropenia and infection in pediatric oncology patients with chemotherapy. Pediatr. Blood Cancer 2011, 57:89-96.
31. Frakking F.N., van de Wetering M.D., Brouwer N., Dolman K.M., Geissler J., Lemkes B., Caron H.N., Kuijpers T.W. The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia. Eur. J. Cancer 2006, 42:909-916.
32. Frederiksen P.D., Thiel S., Larsen C.B., Jensenius J.C. M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement. Scand. J. Immunol. 2005, 62:462-473.
33. Garcia-Laorden M.I., Garcia-Saavedra A., de Castro F.R., Violan J.S., Rajas O., Blanquer J., Borderias L., Rodriguez-Gallego C. Low clinical penetrance of mannose-binding lectin-associated serine protease 2 deficiency. J. Allergy Clin. Immunol. 2006, 118:1383-1386.
34. Garred P., Harboe M., Oettinger T., Koch C., Svejgaard A. Dual role of mannan-binding protein in infections: another case of heterosis?. Eur. J. Immunogenet. 1994, 21:125-131.
35. Garred P., J.Strøm J., Quist L., Taaning E., Madsen H.O. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome. J. Infect. Dis. 2003, 188:1394-1403.
36. Garred P., Larsen F., Madsen H.O., Koch C. Mannose-binding lectin deficiency--revisited. Mol. Immunol. 2003, 40:73-84.
37. Garred P., Larsen F., Seyfarth J., Fujita R., Madsen H.O. Mannose-binding lectin and its genetic variants. Genes Immun. 2006, 7:85-94.
38. Garred P., Madsen H.O., Balslev U., Hofmann B., Pedersen C., Gerstoft J., Svejgaard A. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 1997, 349:236-240.
39. Garred P., Pressler T., Lanng S., Madsen H.O., Moser C., Laursen I., Balstrup F., Koch C., Koch C. Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr. Pulmonol. 2002, 33:201-207.
40. Guillot L., Beucher J., Tabary O., Le Rouzic P., Clement A., Corvol H. Lung disease modifier genes in cystic fibrosis. Int. J. Biochem. Cell Biol. 2014, 52:83-93.
41. Haerynck F., Van Steen K., Cattaert T., Loeys B., Van Daele S., Schelstraete P., Claes K., Van Thielen M., De Canck I., Mahachie John J.M., De Baets F. Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients. Hum. Immunol. 2012, 73:1175-1183.
42. Hansen T.K., Thiel S., Wouters P.J., Christiansen J.S., Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J. Clin. Endocrinol. Metab. 2003, 88:1082-1088.
43. Hart M.L., Ceonzo K.A., Shaffer L.A., Takahashi K., Rother R.P., Reenstra W.R., Buras J.A., Stahl G.L. Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J. Immunol. 2005, 174:6373-6380.
44. Hartel C., Deuster M., Lehrnbecher T., Schultz C. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr. Blood Cancer 2007, 49:767-773.
45. Heja D., Kocsis A., Dobo J., Szilagyi K., Szasz R., Zavodszky P., Pal G., Gal P. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:10498-10503.
46. Israels J., Frakking F.N., Kremer L.C., Offringa M., Kuijpers T.W., van de Wetering M.D. Mannose-binding lectin and infection risk in newborns: a systematic review. Arch. Dis. Child. Fetal Neonatal Ed. 2010, 95:F452-F461.
47. Israels J., Scherpbier H.J., Frakking F.N., van de Wetering M.D., Kremer L.C., Kuijpers T.W. Mannose-binding lectin and the risk of HIV transmission and disease progression in children: a systematic review. Pediatr. Infect. Dis. J. 2012, 31:1272-1278.
48. Jensen P.H., Laursen I., Matthiesen F., Hojrup P. Posttranslational modifications in human plasma MBL and human recombinant MBL. Biochim. Biophys. Acta 2007, 1774:335-344.
49. Jensenius H., Klein D.C., van Hecke M., Oosterkamp T.H., Schmidt T., Jensenius J.C. Mannan-binding lectin: structure, oligomerization, and flexibility studied by atomic force microscopy. J. Mol. Biol. 2009, 391:246-259.
50. Kase T., Suzuki Y., Kawai T., Sakamoto T., Ohtani K., Eda S., Maeda A., Okuno Y., Kurimura T., Wakamiya N. Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology 1999, 97:385-392.
51. Kaur S., Gupta V.K., Thiel S., Sarma P.U., Madan T. Protective role of mannan-binding lectin in a murine model of invasive pulmonary aspergillosis. Clin. Exp. Immunol. 2007, 148:382-389.
52. Kawasaki T., Etoh R., Yamashina I. Isolation and characterization of a mannan-binding protein from rabbit liver. Biochem. Biophys. Res. Commun. 1978, 81:1018-1024.
53. Keizer M.P., Kamp A.M., Brouwer N., van de Wetering M.D., Wouters D., Kuijpers T.W. Plasma-derived mannose-binding lectin shows a direct interaction with C1-inhibitor. Mol. Immunol. 2014, 58:187-193.
54. Krarup A., Thiel S., Hansen A., Fujita T., Jensenius J.C. l-Ficolin is a pattern recognition molecule specific for acetyl groups. J. Biol. Chem. 2004, 279:47513-47519.
55. Larsen F., Madsen H.O., Sim R.B., Koch C., Garred P. Disease-associated mutations in human mannose-binding lectin compromise oligomerization and activity of the final protein. J. Biol. Chem. 2004, 279:21302-21311.
56. Laursen I. Mannan-binding lectin (MBL) production from human plasma. Biochem. Soc. Trans. 2003, 31:758-762.
57. Lawn J.E., Cousens S., Zupan J., Lancet Neonatal Survival Steering T. 4 Million neonatal deaths: when? where? why?. Lancet 2005, 365:891-900.
58. Lee S.G., Yum J.S., Moon H.M., Kim H.J., Yang Y.J., Kim H.L., Yoon Y., Lee S., Song K. Analysis of mannose-binding lectin 2 (MBL2) genotype and the serum protein levels in the Korean population. Mol. Immunol. 2005, 42:969-977.
59. Lennemann N.J., Rhein B.A., Ndungo E., Chandran K., Qiu X., Maury W. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. mBio 2014, 5:e00862-e913.
60. Lipscombe R.J., Sumiya M., Hill A.V., Lau Y.L., Levinsky R.J., Summerfield J.A., Turner M.W. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum. Mol. Genet. 1992, 1:709-715.
61. Lu J.H., Thiel S., Wiedemann H., Timpl R., Reid K.B. Binding of the pentamer/hexamer forms of mannan-binding protein to zymosan activates the proenzyme C1r2C1s2 complex, of the classical pathway of complement, without involvement of C1q. J. Immunol. 1990, 144:2287-2294.
62. Madsen H.O., Garred P., Kurtzhals J.A., Lamm L.U., Ryder L.P., Thiel S., Svejgaard A. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 1994, 40:37-44.
63. Madsen H.O., Garred P., Thiel S., Kurtzhals J.A., Lamm L.U., Ryder L.P., Svejgaard A. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J. Immunol. 1995, 155:3013-3020.
64. Madsen H.O., Satz M.L., Hogh B., Svejgaard A., Garred P. Different molecular events result in low protein levels of mannan-binding lectin in populations from southeast Africa and South America. J. Immunol. 1998, 161:3169-3175.
65. Matsushita M., Ezekowitz R.A., Fujita T. The Gly-54→Asp allelic form of human mannose-binding protein (MBP) fails to bind MBP-associated serine protease. Biochem. J. 1995, 311(Pt 3):1021-1023.
66. Miller M., Seals J., Kaye R., Levitsky L. A familial, plasma-associated defect of phagocytosis: a new cause of recurrent bacterial infections. Lancet 1968, 292:60-63.
67. Mogues T., Ota T., Tauber A.I., Sastry K.N. Characterization of two mannose-binding protein cDNAs from rhesus monkey (Macaca mulatta): structure and evolutionary implications. Glycobiology 1996, 6:543-550.
68. Moller-Kristensen M., Ip W.K., Shi L., Gowda L.D., Hamblin M.R., Thiel S., Jensenius J.C., Ezekowitz R.A., Takahashi K. Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa. J. Immunol. 2006, 176:1769-1775.
69. Mullighan C.G., Heatley S., Doherty K., Szabo F., Grigg A., Hughes T.P., Schwarer A.P., Szer J., Tait B.D., Bik To L., Bardy P.G. Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation. Blood 2002, 99:3524-3529.
70. Naito H., Ma Y., Uemura K., Arano Y., Kawasaki T. Metabolic properties of normal and mutant mannan-binding proteins in mouse plasma. Biochem. Biophys. Res. Commun. 1999, 256:231-234.
71. Nauta A.J., Raaschou-Jensen N., Roos A., Daha M.R., Madsen H.O., Borrias-Essers M.C., Ryder L.P., Koch C., Garred P. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur. J. Immunol. 2003, 33:2853-2863.
72. Neth O., Hann I., Turner M.W., Klein N.J. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001, 358:614-618.
73. Neth O., Jack D.L., Johnson M., Klein N.J., Turner M.W. Enhancement of complement activation and opsonophagocytosis by complexes of mannose-binding lectin with mannose-binding lectin-associated serine protease after binding to Staphylococcus aureus. J. Immunol. 2002, 169:4430-4436.
74. Nielsen S.L., Andersen P.L., Koch C., Jensenius J.C., Thiel S. The level of the serum opsonin, mannan-binding protein in HIV-1 antibody-positive patients. Clin. Exp. Immunol. 1995, 100:219-222.
75. Nilsson B., Nilsson Ekdahl K. The tick-over theory revisited: is C3 a contact-activated protein?. Immunobiology 2012, 217:1106-1110.
76. Olesen H.V., Jensenius J.C., Steffensen R., Thiel S., Schiotz P.O. The mannan-binding lectin pathway and lung disease in cystic fibrosis--disfunction of mannan-binding lectin-associated serine protease 2 (MASP-2) may be a major modifier. Clin. Immunol. 2006, 121:324-331.
77. Olszowski T., Poziomkowska-Gesicka I., Jensenius J.C., Adler G. Lectin pathway of complement activation in a Polish woman with MASP-2 deficiency. Immunobiology 2014, 219:261-262.
78. Ozkan H., Koksal N., Cetinkaya M., Kilic S., Celebi S., Oral B., Budak F. Serum mannose-binding lectin (MBL) gene polymorphism and low MBL levels are associated with neonatal sepsis and pneumonia. J. Perinatol. 2012, 32:210-217.
79. Pana Z.D., Samarah F., Papi R., Antachopoulos C., Papageorgiou T., Farmaki E., Hatzipantelis E., Tragiannidis A., Vavatsi-Christaki N., Kyriakidis D., Athanassiadou-Piperopoulou F., Roilides E. Mannose binding lectin and ficolin-2 polymorphisms are associated with increased risk for bacterial infections in children with B acute lymphoblastic leukemia. Pediatr. Blood Cancer 2014, 61:1017-1022.
80. Parej K., Hermann A., Donath N., Zavodszky P., Gal P., Dobo J. Dissociation and re-association studies on the interaction domains of mannan-binding lectin (MBL)-associated serine proteases, MASP-1 and MASP-2, provide evidence for heterodimer formation. Mol. Immunol. 2014, 59:1-9.
81. Pavlov V.I., Skjoedt M.O., Siow Tan Y., Rosbjerg A., Garred P., Stahl G.L. Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 2012, 126:2227-2235.
82. Petersen K.A., Matthiesen F., Agger T., Kongerslev L., Thiel S., Cornelissen K., Axelsen M. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J. Clin. Immunol. 2006, 26:465-475.
83. Peterslund N.A., Koch C., Jensenius J.C., Thiel S. Association between deficiency of mannose-binding lectin and severe infections after chemotherapy. Lancet 2001, 358:637-638.
84. PrabhuDas M., Adkins B., Gans H., King C., Levy O., Ramilo O., Siegrist C.A. Challenges in infant immunity: implications for responses to infection and vaccines. Nat. Immunol. 2011, 12:189-194.
85. Rosbjerg A., Munthe-Fog L., Garred P., Skjoedt M.O. Heterocomplex formation between MBL/ficolin/CL-11-associated serine protease-1 and -3 and MBL/ficolin/CL-11-associated protein-1. J. Immunol. 2014, 192:4352-4360.
86. Sallenbach S., Thiel S., Aebi C., Otth M., Bigler S., Jensenius J.C., Schlapbach L.J., Ammann R.A. Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2). Pediatr. Allergy Immunol. 2011, 22:424-430.
87. Sapkota B.R., Macdonald M., Berrington W.R., Misch E.A., Ranjit C., Siddiqui M.R., Kaplan G., Hawn T.R. Association of TNF, MBL, and VDR polymorphisms with leprosy phenotypes. Hum. Immunol. 2010, 71:992-998.
88. Sastry K., Herman G.A., Day L., Deignan E., Bruns G., Morton C.C., Ezekowitz R.A. The human mannose-binding protein gene. Exon structure reveals its evolutionary relationship to a human pulmonary surfactant gene and localization to chromosome 10. J. Exp. Med. 1989, 170:1175-1189.
89. Sato T., Endo Y., Matsushita M., Fujita T. Molecular characterization of a novel serine protease involved in activation of the complement system by mannose-binding protein. Int. Immunol. 1994, 6:665-669.
90. Schelonka R.L., Infante A.J. Neonatal immunology. Semin. Perinatol. 1998, 22:2-14.
91. Schlapbach L.J., Aebi C., Otth M., Luethy A.R., Leibundgut K., Hirt A., Ammann R.A. Serum levels of mannose-binding lectin and the risk of fever in neutropenia pediatric cancer patients. Pediatr. Blood Cancer 2007, 49:11-16.
92. Schlapbach L.J., Aebischer M., Adams M., Natalucci G., Bonhoeffer J., Latzin P., Nelle M., Bucher H.U., Latal B., Swiss Neonatal N., Follow-Up G. Impact of sepsis on neurodevelopmental outcome in a Swiss National Cohort of extremely premature infants. Pediatrics 2011, 128:e348-e357.
93. Schlapbach L.J., Mattmann M., Thiel S., Boillat C., Otth M., Nelle M., Wagner B., Jensenius J.C., Aebi C. Differential role of the lectin pathway of complement activation in susceptibility to neonatal sepsis. Clin. Infect. Dis. 2010, 51:153-162.
94. Schwaeble W.J., Lynch N.J., Clark J.E., Marber M., Samani N.J., Ali Y.M., Dudler T., Parent B., Lhotta K., Wallis R., Farrar C.A., Sacks S., Lee H., Zhang M., Iwaki D., Takahashi M., Fujita T., Tedford C.E., Stover C.M. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7523-7528.
95. Seyfarth J., Garred P., Madsen H.O. Extra-hepatic transcription of the human mannose-binding lectin gene (mbl2) and the MBL-associated serine protease 1-3 genes. Mol. Immunol. 2006, 43:962-971.
96. Shi L., Takahashi K., Dundee J., Shahroor-Karni S., Thiel S., Jensenius J.C., Gad F., Hamblin M.R., Sastry K.N., Ezekowitz R.A. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J. Exp. Med. 2004, 199:1379-1390.
97. Siassi M., Hohenberger W., Riese J. Mannan-binding lectin (MBL) serum levels and post-operative infections. Biochem. Soc. Trans. 2003, 31:774-775.
98. Skjoedt M.O., Hummelshoj T., Palarasah Y., Honore C., Koch C., Skjodt K., Garred P. A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J. Biol. Chem. 2010, 285:8234-8243.
99. Sokolowska A., Szala A., St Swierzko A., Kozinska M., Niemiec T., Blachnio M., Augustynowicz-Kopec E., Dziadek J., Cedzynski M. Mannan-binding lectin-associated serine protease-2 (MASP-2) deficiency in two patients with pulmonary tuberculosis and one healthy control. Cell. Mol. Immunol. 2014, (in press).
100. Steffensen R., Thiel S., Varming K., Jersild C., Jensenius J.C. Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers. J. Immunol. Methods 2000, 241:33-42.
101. Stengaard-Pedersen K., Thiel S., Gadjeva M., Moller-Kristensen M., Sorensen R., Jensen L.T., Sjoholm A.G., Fugger L., Jensenius J.C. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N. Engl. J. Med. 2003, 349:554-560.
102. Stover C., Barrett S., Lynch N.J., Barker J.N., Burden D., Trembath R., Schwaeble W., Veal C. Functional MASP2 single nucleotide polymorphism plays no role in psoriasis. Br. J. Dermatol. 2005, 152:1313-1315.
103. Stover C.M., Schwaeble W.J., Lynch N.J., Thiel S., Speicher M.R. Assignment of the gene encoding mannan-binding lectin-associated serine protease 2 (MASP2) to human chromosome 1p36.3→p36.2 by in situ hybridization and somatic cell hybrid analysis. Cytogenet. Cell Genet. 1999, 84:148-149.
104. Stover C.M., Thiel S., Thelen M., Lynch N.J., Vorup-Jensen T., Jensenius J.C., Schwaeble W.J. Two constituents of the initiation complex of the mannan-binding lectin activation pathway of complement are encoded by a single structural gene. J. Immunol. 1999, 162:3481-3490.
105. Sugimoto R., Yae Y., Akaiwa M., Kitajima S., Shibata Y., Sato H., Hirata J., Okochi K., Izuhara K., Hamasaki N. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J. Biol. Chem. 1998, 273:20721-20727.
106. Sumiya M., Super M., Tabona P., Levinsky R.J., Arai T., Turner M.W., Summerfield J.A. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991, 337:1569-1570.
107. Summerfield J.A., Sumiya M., Levin M., Turner M.W. Association of mutations in mannose binding protein gene with childhood infection in consecutive hospital series. BMJ 1997, 314:1229-1232.
108. Super M., Gillies S.D., Foley S., Sastry K., Schweinle J.E., Silverman V.J., Ezekowitz R.A. Distinct and overlapping functions of allelic forms of human mannose binding protein. Nat. Genet. 1992, 2:50-55.
109. Super M., Thiel S., Lu J., Levinsky R.J., Turner M.W. Association of low levels of mannan-binding protein with a common defect of opsonisation. Lancet 1989, 2:1236-1239.
110. Takahashi M., Endo Y., Fujita T., Matsushita M. A truncated form of mannose-binding lectin-associated serine protease (MASP)-2 expressed by alternative polyadenylation is a component of the lectin complement pathway. Int. Immunol. 1999, 11:859-863.
111. Takahashi M., Ishida Y., Iwaki D., Kanno K., Suzuki T., Endo Y., Homma Y., Fujita T. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 2010, 207:29-37.
112. Teh C., Le Y., Lee S.H., Lu J. M-ficolin is expressed on monocytes and is a lectin binding to N-acetyl-d-glucosamine and mediates monocyte adhesion and phagocytosis of Escherichia coli. Immunology 2000, 101:225-232.
113. Terai I., Kobayashi K. Perinatal changes in serum mannose-binding protein (MBP) levels. Immunol. Lett. 1993, 38:185-187.
114. Terai I., Kobayashi K., Matsushita M., Miyakawa H., Mafune N., Kikuta H. Relationship between gene polymorphisms of mannose-binding lectin (MBL) and two molecular forms of MBL. Eur. J. Immunol. 2003, 33:2755-2763.
115. Thiel S., Holmskov U., Hviid L., Laursen S.B., Jensenius J.C. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. Clin. Exp. Immunol. 1992, 90:31-35.
116. Thiel S., Steffensen R., Christensen I.J., Ip W.K., Lau Y.L., Reason I.J., Eiberg H., Gadjeva M., Ruseva M., Jensenius J.C. Deficiency of mannan-binding lectin associated serine protease-2 due to missense polymorphisms. Genes Immun. 2007, 8:154-163.
117. Thielens N.M., Cseh S., Thiel S., Vorup-Jensen T., Rossi V., Jensenius J.C., Arlaud G.J. Interaction properties of human mannan-binding lectin (MBL)-associated serine proteases-1 and -2, MBL-associated protein 19, and MBL. J. Immunol. 2001, 166:5068-5077.
118. Thielens N.M., Tacnet-Delorme P., Arlaud G.J. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology 2002, 205:563-574.
119. Thomas H.C., Foster G.R., Sumiya M., McIntosh D., Jack D.L., Turner M.W., Summerfield J.A. Mutation of gene of mannose-binding protein associated with chronic hepatitis B viral infection. Lancet 1996, 348:1417-1419.
120. Turner M.W. Deficiency of mannan binding protein - a new complement deficiency syndrome. Clin. Exp. Immunol. 1991, 86(Suppl. 1):53-56.
121. Turner M.W. The lectin pathway of complement activation. Res. Immunol. 1996, 147:110-115.
122. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem. Soc. Trans. 2003, 31:768-769.
123. Valdimarsson H., Stefansson M., Vikingsdottir T., Arason G.J., Koch C., Thiel S., Jensenius J.C. Reconstitution of opsonizing activity by infusion of mannan-binding lectin (MBL) to MBL-deficient humans. Scand. J. Immunol. 1998, 48:116-123.
124. Valdimarsson H., Vikingsdottir T., Bang P., Saevarsdottir S., Gudjonsson J.E., Oskarsson O., Christiansen M., Blou L., Laursen I., Koch C. Human plasma-derived mannose-binding lectin: a phase I safety and pharmacokinetic study. Scand. J. Immunol. 2004, 59:97-102.
125. Verdu P., Barreiro L.B., Patin E., Gessain A., Cassar O., Kidd J.R., Kidd K.K., Behar D.M., Froment A., Heyer E., Sica L., Casanova J.L., Abel L., Quintana-Murci L. Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum. Mol. Genet. 2006, 15:2650-2658.
126. Vigerust D.J., Shepherd V.L. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol. 2007, 15:211-218.
127. Viscoli C., Castagnola E. Treatment of febrile neutropenia: what is new?. Curr. Opin. Infect. Dis. 2002, 15:377-382.
128. Vorup-Jensen T., Sorensen E.S., Jensen U.B., Schwaeble W., Kawasaki T., Ma Y., Uemura K., Wakamiya N., Suzuki Y., Jensen T.G., Takahashi K., Ezekowitz R.A., Thiel S., Jensenius J.C. Recombinant expression of human mannan-binding lectin. Int. Immunopharmacol. 2001, 1:677-687.
129. Wagner S., Lynch N.J., Walter W., Schwaeble W.J., Loos M. Differential expression of the murine mannose-binding lectins A and C in lymphoid and nonlymphoid organs and tissues. J. Immunol. 2003, 170:1462-1465.
130. Wahab Mohamed W.A., Saeed M.A. Mannose-binding lectin serum levels in neonatal sepsis and septic shock. J. Matern.-Fetal Neonatal Med. 2012, 25:411-414.
131. Weiler C.A., Drumm M.L. Genetic influences on cystic fibrosis lung disease severity. Front. Pharmacol. 2013, 4:40.
132. Ying H., Ji X., Hart M.L., Gupta K., Saifuddin M., Zariffard M.R., Spear G.T. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res. Hum. Retroviruses 2004, 20:327-335.
133. Ytting H., Christensen I.J., Basse L., Lykke J., Thiel S., Jensenius J.C., Nielsen H.J. Influence of major surgery on the mannan-binding lectin pathway of innate immunity. Clin. Exp. Immunol. 2006, 144:239-246.
134. Yuen M.F., Lau C.S., Lau Y.L., Wong W.M., Cheng C.C., Lai C.L. Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. Hepatology 1999, 29:1248-1251.
135. Zemanick E.T., Harris J.K., Conway S., Konstan M.W., Marshall B., Quittner A.L., Retsch-Bogart G., Saiman L., Accurso F.J. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J. Cyst. Fibros. 2010, 9:1-16.